公司資料
Camurus 股價、新聞與催化劑
- 股票代碼:
- CAMX
- 交易所:
- NASDAQ
- 產業:
- Biotechnology
- 所在地:
- United States
股票表現
35.79 USD (-1.43%)
收盤價
最後更新: 2026年8月17日
—
市值
股價為何變動
As of Aug 17, 2026, CAMX closed down 1.43% at $35.79. No new same-company headline was identified in the current news window.
公司概覽
Long-Acting Medicines Platform
Camurus is an international biopharmaceutical company that develops and commercializes long-acting medicines for severe and chronic diseases. Its products and candidates combine the proprietary FluidCrystal drug-delivery technology with active pharmaceutical ingredients to create differentiated extended-release formulations. The company is headquartered in Lund, Sweden, and operates across Europe, the United States, and Australia.
Opioid-Dependence Franchise
Buvidal is a weekly or monthly injectable buprenorphine treatment for opioid dependence that is commercialized across Europe, Australia, and the MENA region. The same product is marketed in the United States as Brixadi by partner Braeburn, providing Camurus with a royalty-based position in the US opioid-use-disorder market.
Acromegaly Commercial Portfolio
Oczyesa is a once-monthly, self-administered octreotide depot approved in the European Union and United Kingdom for maintenance treatment of acromegaly. The product uses a ready-to-use autoinjector and is designed to replace clinic-administered somatostatin-receptor-ligand injections. Commercial rollout began in Germany and is expanding into Sweden and the United Kingdom.
CAM2029 Multi-Indication Development
CAM2029 is the underlying octreotide-depot program for Oczyesa and the proposed US product Oclaiz. Beyond acromegaly, Camurus is evaluating CAM2029 in the Phase 3 SORENTO study for gastroenteropancreatic neuroendocrine tumors and in the Phase 2b POSITANO program for polycystic liver disease. The SORENTO study compares CAM2029 with current first-line somatostatin-receptor-ligand therapies in patients with metastatic or unresectable disease.
Metabolic and Partnered Pipeline
CAM2056 is a once-monthly semaglutide depot being developed for overweight, obesity, and other metabolic diseases after completing a Phase 1b study. Camurus is also applying FluidCrystal through partnerships with Eli Lilly on long-acting incretin and amylin-receptor-agonist products, with Rhythm Pharmaceuticals on CAM4072 for genetic obesity disorders, and with Gubra on a long-acting parathyroid-hormone analogue for hypoparathyroidism.
未來催化劑
- Primary results from the Phase 3 SORENTO study of CAM2029 in GEP-NET after the target 194 progression-free-survival events, expected beginning in the fourth quarter of 2026.
- Decision on advancing CAM2029 into Phase 3 development for polycystic liver disease later in 2026.
- Initiation of the Phase 2b study of monthly semaglutide depot CAM2056 in the second half of 2026.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。